A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
Status:
Not yet recruiting
Trial end date:
2023-02-24
Target enrollment:
Participant gender:
Summary
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week
16 in participants with moderate-to-severe plaque psoriasis.